Stock 301333 R&G PHARMASTUDIES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings R&G PharmaStudies Co., Ltd.

Equities

301333

CNE100005K44

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
44.04 CNY -2.20% Intraday chart for R&G PharmaStudies Co., Ltd. +0.62% -31.70%
Apr. 21 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • With a 2024 P/E ratio at 24.6 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
R&G PHARMASTUDIES CO., LTD. Stock R&G PharmaStudies Co., Ltd.
-31.70% 597M -
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+17.74% 82.59B
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-29.66% 69.86B
B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
0.00% 26.5B
C+
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+3.06% 17.29B
A-
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-12.16% 16.61B
B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+2.47% 15.56B
A-
NATERA, INC. Stock Natera, Inc.
+74.82% 13.2B
C-
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
+0.76% 12.75B
B-
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+73.52% 12.6B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 301333 Stock
  4. Ratings R&G PharmaStudies Co., Ltd.